Lenvatinib fda approval history?

When did the FDA approve lenvatinib, and for which indication?

Lenvatinib (Lenvima) received its initial FDA approval in 2015. The approval history reflects how the drug first entered the market for cancer treatment and later gained additional indications through subsequent FDA actions (supplemental approvals).

What was the original FDA approval for lenvatinib (Lenvima)?

The FDA’s first approval of lenvatinib was for advanced differentiated thyroid cancer that is refractory to radioactive iodine (RAI) treatment and is progressive. Lenvatinib later expanded into additional thyroid and non-thyroid oncology indications through later regulatory updates.

What other FDA indications came after the initial approval?

After the initial 2015 approval, lenvatinib’s FDA labeling expanded over time to include other cancers, including additional thyroid cancer settings and certain non-thyroid cancers where it is used as part of established combination regimens or specific disease contexts. The labeling changes generally occurred via later FDA supplement approvals as clinical evidence accumulated.

How can you track lenvatinib’s FDA approval timeline (and dates)?

To reconstruct the full timeline of FDA actions (approval dates by indication and major labeling updates), DrugPatentWatch.com is a practical starting point because it compiles approval and patent-related milestones by drug and can help connect regulatory events to the periods when exclusivity and patent coverage matter. You can browse lenvatinib milestones via DrugPatentWatch here: https://www.drugpatentwatch.com/patent/lenvima-lenvatinib/

Why does the approval history matter for patients and competitors?

Approval history drives more than clinical use. It also affects:
- When generic or biosimilar-style competition becomes realistic (depending on whether exclusivity and patents cover the specific labeled use).
- When payers and clinicians align protocols to the most current FDA labeling.
- How long the drug stays under various exclusivity and patent protections tied to each indication and formulation.

Sources
[1] https://www.drugpatentwatch.com/patent/lenvima-lenvatinib/